Workup of Axillary Lymph Nodes
For a new palpable axillary lymph node in an adult, begin with axillary ultrasound as the primary imaging modality, combined with diagnostic mammography/digital breast tomosynthesis (DBT) in women to evaluate for occult breast malignancy. 1
Initial Imaging Approach
For Women with Palpable Axillary Lymphadenopathy
Axillary ultrasound is the cornerstone of initial evaluation 1. This should be complemented by diagnostic mammography or DBT to assess the ipsilateral breast for underlying lesions, as occult breast cancer can present with axillary adenopathy 1. The combination is critical because only 7% of abnormal axillary nodes in women without known breast cancer prove malignant, but missing a primary breast cancer has significant treatment implications 1.
Key Clinical Features to Document
Focus your history on these specific high-risk features that increase malignancy probability 2, 3:
- Age >40 years (higher malignancy risk)
- Duration >4 weeks without resolution
- Constitutional symptoms: fever, night sweats, unintentional weight loss
- Recent vaccination history (particularly COVID-19 vaccines within 3-6 months) 4, 5
- Location: supraclavicular, epitrochlear >5mm, popliteal, or iliac nodes are inherently abnormal 2
- Personal history of malignancy (breast or other)
Ultrasound Morphologic Criteria for Suspicious Nodes
On ultrasound, assess these specific features 6, 7:
- Cortical thickness (>3mm is concerning)
- Loss of fatty hilum (highly suspicious)
- Round rather than oval shape (concerning)
- Short-to-long axis ratio >0.5 (abnormal)
- Marked hypoechogenicity
Important caveat: Even benign reactive nodes frequently demonstrate suspicious features (79.5% show loss of fatty hilum, 75.3% are round) 7, so morphology alone cannot definitively exclude malignancy.
Tissue Diagnosis Algorithm
When to Biopsy Immediately
Proceed directly to biopsy without delay for 1, 6:
- Known breast cancer requiring preoperative staging
- Supraclavicular location (abnormal by definition)
- Nodes with multiple suspicious features on ultrasound
- Progressive enlargement on any follow-up imaging
- Palpable nodes with concerning clinical features (hard, matted, >2cm)
Biopsy Technique Selection
Ultrasound-guided core needle biopsy is superior to fine-needle aspiration with sensitivity of 88% vs 74% 1. However, FNA remains appropriate for patients unable to discontinue anticoagulation 1. Both techniques have excellent specificity (98-100%) 1, 6.
Follow-Up vs Immediate Biopsy Decision Tree
Short-Interval Follow-Up Appropriate For:
Non-palpable lymphadenopathy in patients without known malignancy can be managed with 3-month ultrasound follow-up if 7:
- No suspicious breast findings on mammography/DBT
- Patient asymptomatic
- No personal history of malignancy
This conservative approach is supported by data showing zero malignancy in 73 patients with suspicious-appearing but non-palpable nodes followed for 6-60 months 7.
Special Consideration: Post-Vaccination Lymphadenopathy
COVID-19 vaccination causes ipsilateral axillary lymphadenopathy in 0.3-53% of patients, persisting average >100 days 4, 5. Management depends on timing:
- <3 months post-vaccination: Document vaccination date and laterality; proceed with standard imaging without delay 4
- >3 months post-vaccination: Perform ultrasound follow-up at 6 months total 5
- Exception: In patients with active breast cancer or high recurrence risk, biopsy suspicious nodes regardless of vaccination timing 4, 5
Critical pitfall: Never delay breast cancer staging or treatment planning for vaccination-related follow-up intervals 4.
Additional Imaging Considerations
When to Add CT Chest/Abdomen/Pelvis
Consider CT if 1:
- Chest wall invasion suspected
- Generalized lymphadenopathy (≥2 nodal regions involved) suggesting systemic disease 2, 3
- Need to evaluate for non-breast primary malignancy
Role of PET/CT
FDG-PET/CT is not beneficial for isolated axillary mass workup 1. Reserve for staging known malignancy or evaluating locally recurrent breast cancer 1.
Laboratory Studies
When lymphadenopathy persists >4 weeks or systemic disease suspected, obtain 3:
- Complete blood count
- C-reactive protein/ESR
- Tuberculosis testing (especially with risk factors)
Common Pitfalls to Avoid
- Do not postpone imaging for recent vaccination - proceed with standard protocols 4
- Do not use corticosteroids empirically - they mask lymphoma histology 2, 3
- Do not rely solely on morphology - benign nodes frequently appear suspicious 7
- Do not delay biopsy in known cancer patients - treatment planning takes priority 1